Andrew M. Brunner, MD | Authors


Sabatolimab Appears Promising for Combination Use With HMAs in AML, MDS

December 25, 2020

Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.